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Management of Iron-Deficiency Anemia on Inpatients and 
Appropriate Discharge and Follow-Up
Kishan Patela, b, Zain Memona, Rebecca Mazurkiewicza
Abstract
Background: The aims of the study were to identify appropriate sup-
plementation of iron for inpatients and to identify factors involved in 
appropriate discharge documentation and follow-up.
Methods: This was a retrospective analysis of 103 patients at a com-
munity hospital in New York City.
Results: A total of 57 (57/103, 55.3%) patients were admitted due 
to symptomatic anemia. Twenty (20/103, 19.4%) of those with 
iron-deficiency anemia had either esophagogastroduodenoscopy or 
colonoscopy. Gastroenterologist or hematologist was consulted for 
45/103 (43.7%). Inpatient iron supplementation was given for 62/103 
(60.2%) of patients; and 43/103 (41.7%) had blood transfusion. Upon 
discharge, 50/103 (48.5%) had appropriate documentation of iron-
deficiency anemia on discharge paperwork. Appropriate follow-up 
was done for 54/103 (52.4%). Iron supplementation was provided for 
53/103 (51.5%) of patients. Having inpatient esophagogastroduoden-
oscopy or colonoscopy, blood transfusion, or symptomatic anemia 
had a statistical significance for likelihood of appropriate discharge 
documentation.
Conclusions: Iron-deficiency anemia can have high rates of mortal-
ity and morbidity in the population. Appropriate discharge of patients 
with iron-deficiency anemia and factors related to this are paramount 
for clinicians in order to have the best patient outcomes.
Keywords: Iron-deficiency anemia; Congestive heart failure; Chron-
ic kidney disease; Iron supplementation; Inpatient
Introduction
Anemia is defined by hemoglobin levels under 13 g/dL in men, 
and under 12 g/dL in women [1]. Anemia affects roughly 25% 
of the world population [2, 3], of which half is caused by iron 
deficiency, with 2% of American men and 5% of American 
women affected [2, 3]. Low iron store causes decreased levels 
of hemoglobin production by the bone marrow [2]. Iron is re-
quired for erythrocytes to produce heme for hemoglobin and 
for vital proteins in oxygen transportation [2-5]. Metabolically 
active cells, including myocytes, are highly dependent on this.
Previous literature has shown that in patients with un-
treated iron-deficiency anemia if severe enough, mortality is 
possible due to either poor tissue oxygenation, or cardiac ar-
rhythmias from left ventricular hypertrophy. There is also high 
morbidity due to decreased exercise tolerance, increased fa-
tigue, and worsened quality of life index [2, 6, 7].
Iron-deficiency anemia has been poorly diagnosed and 
treated in inpatients in the past with only 40-66% receiving 
adequate iron supplementation in tertiary care hospitals [8]. 
We hypothesized that patients whose admission to our institu-
tion revealed a new diagnosis of iron-deficiency anemia would 
not be reliably discharged on iron supplementation or have the 
diagnosis appropriately transmitted to their primary care phy-
sicians for further evaluation and treatment.
Materials and Methods
We performed a chart review of patients admitted to our aca-
demic community hospital in New York City who were dis-
charged from the internal medicine service from January to 
June 2018, whose test results met criteria for iron-deficiency 
anemia during that hospital stay. Iron deficiency criterion for 
men was defined as hemoglobin under 13 g/dL, and women 
under 12 g/dL, with ferritin less than 30 ng/dL [1-3, 9] for any 
patient. Diagnostic criteria in patients with congestive heart 
failure were ferritin below 300 ng/dL and transferrin satura-
tion (TSAT) under 20% [10-18]. Diagnostic criteria for those 
with chronic kidney disease were ferritin under 100 ng/dL, and 
TSAT under 20% [19-22]. Those with end stage renal disease 
had iron-deficiency anemia criteria of ferritin under 200 and 
TSAT under 20% [22]. The study excluded those with an al-
lergy to iron.
Patients’ charts were reviewed for inpatient supplemen-
tation of iron, discharge supplementation on paperwork, and 
documentation of iron-deficiency anemia. Patients’ charts 
were also assessed to see rates of hematology and gastroen-
terology consults. Rates of blood transfusions, esophagogas-
troduodenoscopy (EGD), or colonoscopies performed were 
analyzed. This also reviewed if need for EGD or colonoscopy, 
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blood transfusions, or reason for admission was symptomatic 
anemia if there was a statistical relationship with discharge 
documentation. We used Chi-squared, relative risk (RR), and 
odds ratio (OR) to analyze this.
All personal information for patients was de-identified. 
This paper conforms to the Declaration of Helsinki. Institu-
tional Review Board approval was obtained by Feinstein Insti-
tute for Medical Research.
Results
A total of 103 patients were examined, with females 75 
(72.8%) and males 28 (27.2%) (Table 1). Demographic break-
down showed that Caucasians 41 (39.8%), African American 
39 (37.8%); six patients (5.8%) were Asian, nine (8.7%) La-
tino, and eight (7.8%) were other (Table 1). The average age 
was 62.6 years for all patients, with females 60.6 years old and 
males 68.0 years old.
Of 103 patients discharged, 57/103 (55.3%) were admit-
ted due to symptomatic anemia including: gastrointestinal or 
genitourinary bleeding, syncope, lightheadedness, or weak-
ness. Colonoscopy or EGD during hospitalization was done 
on 20/103 (19.4%) of the patients. Either gastroenterologist 
or hematologist was consulted for 45/103 (43.7%) of the pa-
tients. Inpatient iron supplementation was done with 62/103 
(60.2%) of the patients. Oral ferrous sulfate supplementations 
were given in 21/103 (20.4%) of these patients (Table 2). 
Intravenous iron sucrose was given to 33/103 (32%) of the 
patients (Table 2). Intravenous sodium ferric gluconate was 
given to 8/103 (7.8%) of the patients (Table 2). Forty-three 
(43/103, 41.7%) had blood transfusion inpatient, and 34/43 
(79%) of those with blood transfusion had inpatient iron sup-
plementation.
Upon discharge, 50/103 (48.5%) had the term iron-defi-
ciency anemia documented (Table 2). Appropriate follow-up 
with primary care, gastroenterology, obstetrician and gy-
necologist, or hematologist was done for 54/103 (52.4%) of 
the patients (Table 2). Oral iron was supplemented to 53/103 
(51.5%) of the patients (Table 2).
Of those with EGD or colonoscopy, 18/20 (90%) had ap-
propriate discharge documentation of iron-deficiency anemia. 
Of those without the procedure, 32/83 (38.6%) had appropriate 
discharge documentation. P value was < 0.001 (RR was 2.3 
and OR was 14.3, Table 3). These findings showed that hav-
ing an EGD or colonoscopy had a positive relationship with 
likelihood of appropriate mention of iron-deficiency anemia 
on discharge paperwork.
Of those with symptomatic anemia, 38/57 (66.7%) had ap-
propriate discharge documentation. Of those without sympto-
matic anemia, 12/46 (26.1%) had appropriate discharge docu-
mentation. P value was < 0.001 (RR 2.56 and OR 5.67, Table 
3).
Of those patients with blood transfusions during their hos-
pital course, 29/43 (67.4%) had appropriate discharge docu-
mentation (Table 3). Of those without blood transfusion, 21/60 
(35%) had appropriate discharge documentation. P value was 
0.0012 (RR 1.93 and OR was 2.07, Table 3).
Discussion
Our study found that only 52.4% of those discharge had appro-
priate follow-up with care providers or oral iron supplemen-
tation, and only 48% had appropriate documentation of iron-
deficiency anemia on discharge paperwork. Having a blood 
transfusion, EGD or colonoscopy, or symptomatic anemia had 
a higher likelihood of better discharge documentation.
Table 1.  Demographics (N = 103)
Variables N (%) or result
Gender, N (%)
  Male 28 (27%)
  Female 75 (72.8%)
Race, N (%)
  Caucasian 41 (39.8%)
  African American 39 (37.9%)
  Latino 9 (8.7%)
  Asian 6 (5.8%)
  Other 8 (7.8%)
Age (average, years)
  Male 68.0
  Female 60.6
Table 2.  Inpatient Iron Supplementation and Discharge
Inpatient iron supplementation and discharge N (%)
Any form of iron supplementation inpatient 62 (60.2%)
Oral ferrous sulfate inpatient 21 (20.4%)
Intravenous iron sucrose inpatient 33 (32%)
Intravenous sodium ferric gluconate inpatient 8 (7.8%)
Oral iron supplementation on discharge 53/103 (51.5%)
Appropriate follow-up with primary care physician, hematologist, gastroenterologist, or 
obstetric gynecologist on discharge paperwork or discharged on oral iron supplementation
54 (52.4%)
Proper documentation of iron-deficiency anemia on discharge paperwork 50 (48%)
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Iron-deficiency anemia is a highly prevalent condition in 
the USA. It can put patients at increased risk of death due to 
decreased oxygen transportation, cause cardiac arrhythmias, 
and decrease quality of life [1, 2, 6]. Iron-deficiency anemia 
has been poorly diagnosed and treated in inpatients in the past, 
with only 60-66% receiving adequate iron supplementation 
[8]. Only 60.2% of those who were admitted to the hospital 
with diagnostic criteria of iron-deficiency anemia were sup-
plemented, consistent with prior studies. Our study shows that 
outpatient management of iron-deficiency anemia after dis-
charge is inadequate, and this can place patients at increased 
risk for morbidity and mortality.
The limitations of this study include being a retrospec-
tive chart review of documentation. Iron-deficiency anemia 
is also tricky in patients with chronic diseases. Iron supple-
mentation has been shown to help reduce mortality in those 
with blood loss [2-7]. Iron deficiency due to congestive heart 
failure and chronic kidney disease confers increased fatigue 
and decreased exercise capacity [10-22]. Oral or intrave-
nous supplementation depending on inflammatory markers 
helps patients have a better quality of life. Future studies are 
needed in interventions to help increase iron supplementation 
from clinicians.
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